PREDICTIVE™ -: a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes:: baseline characteristics and predictors of hypoglycaemia from the European cohort

被引:63
作者
Lueddeke, H. -J.
Sreenan, S.
Aczel, S.
Maxeiner, S.
Yenigun, M.
Kozlovski, P.
Gydesen, H.
Dornhorst, A.
机构
[1] Univ London Imperial Coll Sci Technol & Med, Dept Metab Med, London W12 0NN, England
[2] Praxis Luddeke Trauner, Munich, Germany
[3] Connolly Hosp, Dept Endocrinol, Dublin, Ireland
[4] Landeskrankenhaus Feldkirch, Innere Med Abt, Feldkirch, Austria
[5] Schwerpunktpraxis Bosenheim, Bad Krauznach, Germany
[6] Haseki Training & Res Hosp, Dept Endocrinol & Diabet, Clin Internal Med 54, Aksaray, Turkey
[7] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
关键词
diabetes; diabetes treatment; glycaemic control; HbA(1c); insulin analogue; insulin therapy;
D O I
10.1111/j.1463-1326.2006.00677.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: PREDICTIVE (TM) (Predictable Results and Experience in Diabetes through Intensification and Control to Target: An International Variability Evaluation) is a large, multi-national, observational study assessing the safety and efficacy of insulin detemir. We report the study design, population characteristics and baseline observations, including cross-sectional analysis, from 19 911 patients with type 1 or 2 diabetes. Methods: Patients with type 1 or 2 diabetes requiring basal insulin are prescribed insulin detemir and followed up for 12-52 weeks. Data on demographics, haemoglobin A(1c) (HbA(1c)), fasting glucose, within-subject fasting glucose variability and weight are collected from patient records (and/or recall for hypoglycaemia). A negative binomial distribution model is used to assess the influence of predictive/confounding variables on hypoglycaemic episodes in insulin-treated patients at baseline. Multi-factorial analysis of covariance is used to evaluate the association of the variables with current body weight and within-subject fasting glucose variability. Results: Total hypoglycaemic episodes in the 4 weeks prior to study start were 47.5 per patient-year in patients with type 1 and 9.2 per patient-year in patients with type 2 diabetes. The frequency of hypoglycaemia in insulin-treated patients showed a significant, positive association with duration of diabetes, number of insulin injections and fasting glucose variability but was inversely related to HbA(1c), fasting glucose and body mass index. Weight showed a significant positive association with gender (male > female) and insulin dosage. Weight was also positively associated with fasting glucose variability in patients with type 1 diabetes, and age and number of injections in patients with type 2 diabetes. Conclusions: These baseline data showed that, in addition to the established relationship with intensive treatment and HbA(1c), frequency of hypoglycaemia was positively associated with fasting glucose variability. Follow-up data from PREDICTIVE will provide insights on insulin detemir in diabetes management.
引用
收藏
页码:428 / 434
页数:7
相关论文
共 18 条
[1]   Hypoglycemia in the diabetes control and complications trial [J].
不详 .
DIABETES, 1997, 46 (02) :271-286
[2]   Measuring beliefs about taking hypoglycaemic medication among people with Type 2 diabetes [J].
Farmer, A ;
Kinmonth, AL ;
Sutton, S .
DIABETIC MEDICINE, 2006, 23 (03) :265-270
[3]   Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes [J].
Hermansen, K ;
Fontaine, P ;
Kukolja, KK ;
Peterkova, V ;
Leth, G ;
Gall, MA .
DIABETOLOGIA, 2004, 47 (04) :622-629
[4]   Insulin detemir: from concept to clinical experience [J].
Home, P ;
Kurtzhals, P .
EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (03) :325-343
[5]   Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes - A randomized clinical trial [J].
Home, P ;
Bartley, P ;
Russell-Jones, D ;
Hanaire-Broutin, H ;
Heeg, JE ;
Abrams, P ;
Landin-Olsson, M ;
Hylleberg, B ;
Lang, H ;
Draeger, E .
DIABETES CARE, 2004, 27 (05) :1081-1087
[6]   Sources of glucose variability in insulin-treated type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES) [J].
Murata, GH ;
Duckworth, WC ;
Shah, JH ;
Wendel, CS ;
Hoffman, RM .
CLINICAL ENDOCRINOLOGY, 2004, 60 (04) :451-456
[7]   Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure - Results from the DCCT [J].
Purnell, JQ ;
Hokanson, JE ;
Marcovina, SM ;
Steffes, MW ;
Cleary, PA ;
Brunzell, JD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (02) :140-146
[8]   Insulin detemir and insulin aspart:: a promising basal-bolus regimen for type 2 diabetes [J].
Raslová, K ;
Bogoev, M ;
Raz, I ;
Leth, G ;
Gall, MA ;
Hancu, N .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2004, 66 (02) :193-201
[9]   Obesity and cardiovascular risk factors in type 2 diabetes:: results from the Swedish National Diabetes Register [J].
Ridderstråle, M ;
Gudbjörnsdottir, S ;
Eliasson, B ;
Nilsson, PM ;
Cederholm, J .
JOURNAL OF INTERNAL MEDICINE, 2006, 259 (03) :314-322
[10]  
ROBERTSON KJ, 2005, DIABETIC MED S2, V22, P45